CLYM Key Statistics, Chart & Performance
The current stock price of CLYM is 3 USD. In the past month the price increased by 60.43%. In the past year, price increased by 15.38%.
CLYM Latest News, Press Relases and Analysis
CLYM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About CLYM
Company Profile
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Company Info
CLIMB BIO INC
20 William Street, Suite 145
Wellesley Hills MASSACHUSETTS US
Employees: 17
Phone: 18668572596
CLIMB BIO INC / CLYM FAQ
What does CLYM do?
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
What is the current price of CLYM stock?
The current stock price of CLYM is 3 USD. The price increased by 30.43% in the last trading session.
Does CLIMB BIO INC pay dividends?
CLYM does not pay a dividend.
What is the ChartMill rating of CLIMB BIO INC stock?
CLYM has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for CLIMB BIO INC?
CLIMB BIO INC (CLYM) currently has 17 employees.
Can you provide the ownership details for CLYM stock?
You can find the ownership structure of CLIMB BIO INC (CLYM) on the Ownership tab.
What is the Short Interest ratio of CLIMB BIO INC (CLYM) stock?
The outstanding short interest for CLIMB BIO INC (CLYM) is 2.28% of its float.
CLYM Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CLYM. When comparing the yearly performance of all stocks, CLYM is one of the better performing stocks in the market, outperforming 86.68% of all stocks.
CLYM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLYM. While CLYM has a great health rating, there are worries on its profitability.
CLYM Financial Highlights
Over the last trailing twelve months CLYM reported a non-GAAP Earnings per Share(EPS) of -0.76. The EPS increased by 64.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.84% | ||
| ROE | -28.67% | ||
| Debt/Equity | 0 |
CLYM Forecast & Estimates
12 analysts have analysed CLYM and the average price target is 9.38 USD. This implies a price increase of 212.8% is expected in the next year compared to the current price of 3.